Search Results Heading

MBRLSearchResults

mbrl.module.common.modules.added.book.to.shelf
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
    Done
    Filters
    Reset
  • Discipline
      Discipline
      Clear All
      Discipline
  • Is Peer Reviewed
      Is Peer Reviewed
      Clear All
      Is Peer Reviewed
  • Reading Level
      Reading Level
      Clear All
      Reading Level
  • Content Type
      Content Type
      Clear All
      Content Type
  • Year
      Year
      Clear All
      From:
      -
      To:
  • More Filters
      More Filters
      Clear All
      More Filters
      Item Type
    • Is Full-Text Available
    • Subject
    • Publisher
    • Source
    • Donor
    • Language
    • Place of Publication
    • Contributors
    • Location
214 result(s) for "Michelle Herman"
Sort by:
Devotion
\"An affair with a much older voice teacher leads a young girl into early marriage, leaving behind her Brooklyn family and friends for a new life shadowed by her husband's Old World expectations. Decades later, with her child now pursuing an art career in New York, mother and son come to terms with the quiet intimacy they've both resented and cultivated\"--Page 4 of cover.
Safety considerations of gene-based therapies for Alzheimer's disease
Gene-based therapies show increasing promise for the treatment of neurologic disease. In 2016, nusinersen, an RNA-based therapy, was approved for children with spinal muscular atrophy (SMA). Over 200 clinical trials have utilized gene therapy approaches for a host of neurodegenerative and neuromuscular disorders, including Alzheimer's disease (AD). Delivering gene-based therapies to the central nervous system (CNS) has raised safety concerns. As clinical trials utilizing gene therapy paradigms are undertaken and as approved therapies translate into clinics, a better understanding of safety issues and monitoring parameters is needed. We describe current therapeutic approaches for AD using gene-based therapies such as adeno-associated virus gene therapy and RNA interference by antisense oligonucleotides (ASOs) and undertake a review of medical safety considerations for existing AD gene therapy trials. We identify challenges in analyzing medical safety data currently available and provide guidelines for making this information more accessible and interpretable for the future.
Stories We Tell Ourselves
The two thought-provoking, extended essays that make upStories We Tell Ourselvesdraw from the author's richly diverse experiences and history, taking the reader on a deeply pleasurable walk to several unexpectedly profound destinations. A steady accumulation of fascinating science, psychoanalytic theory, and cultural history-ranging as far and wide as neuro-ophthalmology, ancient dream interpretation, and the essential differences between Jung and Freud-is smoothly intermixed with vivid anecdotes, entertaining digressions, and a disarming willingness to risk everything in the course of a revealing personal narrative. \"Dream Life\" plumbs the depth of dreams-conceptually, biologically, and as the nursery of our most meaningful metaphors-as it considers dreams and dreaming every whichway: from the haruspicy of the Roman Empire to contemporary sleep and dream science, from the way birds dream to the way babies do, from our longing to tell them to the reasons we wish other people wouldn't. \"Seeing Things\" recounts a journey of mother and daughter-a Holmes-and-Watson pair intrepidly working their way through the mysteries of a disorder known as Alice in Wonderland Syndrome-even as it restlessly detours into the world beyond the looking glass of the unconscious itself. In essays that constantly offer layers of surprises and ever-deeper insights, the author turns a powerful lens on the relationships that make up a family, on expertise and unsatisfying diagnoses, on science and art and the pleasures of contemplation and inquiry-and on our fears, regrets, hopes, and (of course) dreams.
Truth, Truthiness, Memory, and Bald-faced Lies—and the Pleasures of Uncertainty
Getting to step out for once from behind the tree-or from inside the closet-wherever I had to hide myself when I wrote fiction (as an invisible third-person narra- tor, say, or behind the persona of an invented first-person narrator) and speak my mind, telling readers, for example, what it was I planned to tell my daughter when she was old enough: that even when love comes to nothing, love makes you more than you were before. What I mean by interesting, I think, is meaning- ful.iii That meaningfulness-like beauty; like love-can be found in a variety of surprising places isn't news to any writer-or to any artist, working in any discipline.
Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease
INTRODUCTION Bumetanide, a loop diuretic, was identified as a candidate drug for repurposing for Alzheimer's disease (AD) based on its effects on transcriptomic apolipoprotein E signatures. Cross‐sectional analyses of electronic health records suggest that bumetanide is associated with decreased prevalence of AD; however, temporality between bumetanide exposure and AD development has not been established. METHODS We evaluated Medicare claims data using Cox proportional hazards regression to evaluate the association between time‐dependent use of bumetanide and time to first AD diagnosis while controlling for patient characteristics. Multiple sensitivity analyses were conducted to test the robustness of the findings. RESULTS We sampled 833,561 Medicare beneficiaries, 60.8% female, with mean (standard deviation) age of 70.4 (12). Bumetanide use was not significantly associated with AD risk (hazard ratio 1.05; 95% confidence interval, 0.99–1.10). DISCUSSION Using a nationwide dataset and a retrospective cohort study design, we were not able to identify a time‐dependent effect of bumetanide lowering AD risk. Highlights Bumetanide was identified as a candidate for repurposing for Alzheimer's disease (AD). We evaluated the association between bumetanide use and risk of AD. We used Medicare data and accounted for duration of bumetanide use. Bumetanide use was not significantly associated with risk of AD.
No Place Like Home
The apartment building I moved into was tiny-a dollhouse of a building-and crumbling, and tilting: if you set a pencil down near the north wall of my apartment, the one wall that had windows (two of them, which looked out on a weedy square of courtyard), it quickly rolled south into the \"kitchen,\" a shallow alcove housing just a miniature stove and sink. I don't tell him that I'm doubtful it would make much of a difference to him, that even if he had his trailer or converted gas station or tin-roof bunker or whatever his dream house turned out to be by then, and it was in the desert or right smack in the middle of a giant field with just a stand or two of pine trees and no neighbors for miles, the sun coming straight up over the horizon every morning without having to work its way past buildings or mountains, he'd still be waiting to feel at home.